TAP1 deficiency creates new immunotherapy targets in colorectal cancer

◇ RESEARCH

Loss of TAP1, an immune escape mechanism found in 26% of colorectal cancers, generates alternative T cell epitopes that may be exploitable for immunotherapy; researchers identified CD8 T cells from patient tumors that can target TAP1-deficient cancer cells. (Molecular Therapy Oncology)